Cancer is a complex disease, one whose pathology can involve many genetic mutations over time. Better understanding of the mechanisms associated with these genetic changes would aid the development of novel and effective diagnostic and therapeutic tools for the fight against cancer. Long non-coding RNAs (lncRNAs) are genetic regulatory molecules associated with cancer occurrence and progression, representing attractive therapeutic targets for cancer therapy. Understanding the role of lncRNAs in the development and progression of cancer may lead to better tools for diagnosis and treatment of cancer.
Guo, W., Wang, Y., Yang, M., Wang, Z., Wang, Y., Chaurasia, S., Wu, Z., Zhang, M., Yadav, G. S., Rathod, S., Concha-Benavente, F., Fernandez, C., Li, S., Xie, W., Ferris, R. L., Kammula, U. S., Lu, B., & Yang, D. (2021). LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Science Advances, 7(7). https://doi.org/10.1126/sciadv.abb3555
Wang, Y., Zhang, M., Wang, Z., Guo, W., & Yang, D. (2020). MYC‐binding lncRNA EPIC1 promotes AKT‐mTORC1 signaling and rapamycin resistance in breast and ovarian cancer. Molecular Carcinogenesis, 59(10), 1188–1198. https://doi.org/10.1002/mc.23248
Wang, Z., Yang, B., Zhang, M., Guo, W., Wu, Z., Wang, Y., Jia, L., Li, S., Xie, W., Yang, D., Caesar-Johnson, S. J., Demchok, J. A., Felau, I., Kasapi, M., Ferguson, M. L., Hutter, C. M., Sofia, H. J., Tarnuzzer, R., Wang, Z., … Mariamidze, A. (2018). lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 33(4), 706-720.e9. https://doi.org/10.1016/j.ccell.2018.03.006
Wang, Y., Wang, Z., Xu, J., Li, J., Li, S., Zhang, M., & Yang, D. (2018). Systematic identification of non-coding pharmacogenomic landscape in cancer. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-05495-9